DOCSLIB.ORG

International Conference on Malignancies in HIV/AIDS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
International Conference on Malignancies in HIV/AIDS th International Conference on 17 Malignancies in HIV/AIDS October 21-22, 2019 NIH Campus Bethesda, Maryland O˜ce of HIV and AIDS Malignancy | National Cancer Institute National Institutes of Health | U.S. Department of Health and Human Services PROGRAM Day 1: October 21 8:00 a.m. – 8:15 a.m. Day 1 Poster Setup Highlighted Posters (1-8) will stay up for the entire meeting. 8:15 a.m. – 8:20 a.m. Welcome and Introduction Robert Yarchoan, M.D. Director Office of HIV and AIDS Malignancy National Cancer Institute, NIH 8:20 a.m. – 8:30 a.m. Opening Remarks Douglas R. Lowy, M.D. Acting Director National Cancer Institute, NIH 8:30 a.m. – 8:35 a.m. Presentation of NCI Director’s Career Achievement Award to Drs. Patrick S. Moore and Yuan Chang 8:35 a.m. – 9:00 a.m. Plenary 1: 25 Years of KSHV Research Patrick S. Moore, M.D., M.P.H. University of Pittsburgh 9:00 a.m. – 10:00 a.m. Session 1: Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) Moderators: Paul M. Lieberman, Ph.D. The Wistar Institute Thomas S. Uldrick, M.D., M.S. National Cancer Institute, NIH 9:00 a.m. – 9:15 a.m. O1. Functional Analysis of Human and Viral Circular RNAs During Kaposi’s Sarcoma Herpesvirus Infection Takanobu Tagawa, Ph.D. National Cancer Institute, NIH 9:15 a.m. – 9:30 a.m. O2. KSHV Manipulates Host Iron Metabolism and Antioxidant Pathways to Promote Tumorigenesis and Resist Ferroptotic Cell Death Ashlee V. Moses, Ph.D. Oregon Health & Science University 9:30 a.m. – 9:45 a.m. O3. Induction of Kaposi’s Sarcoma-Associated Herpesvirus-Encoded Thymidine Kinase (ORF21) by X-Box Binding Protein-1 Robert Yarchoan, M.D. National Cancer Institute, NIH 9:45 a.m. – 10:00 a.m. O4. Characterizing Somatic Cellular Mutations in KS Tumors Warren Phipps, M.D., M.P.H. Fred Hutchinson Cancer Research Center 10:00 a.m. – 10:30 a.m. Break and Poster Viewing - 1 - 10:30 a.m. – 12 noon Session 2: Human Papillomavirus and Associated Diseases Moderators: Joel M. Palefsky, M.D., FRCP(C) University of California, San Francisco Mark H. Einstein, M.D., M.S. Rutgers University 10:30 a.m. – 11:00 a.m. P2. Alternative Outcomes of HPV Infection: Immune Control Versus Neoplastic Progression John Doorbar, M.D. University of Cambridge 11:00 a.m. – 11:30 a.m. P3. Molecular Characteristics of Cervical Cancer in HIV+ and HIV- Ugandan Women Daniela S. Gerhard, Ph.D. National Cancer Institute, NIH 11:30 a.m. – 11:45 a.m. O5. HIV Proteins Gp120 and Tat Induce an Epithelial–Mesenchymal Transition in HPV-Immortalized Anal and Cervical Epithelial Cells and Increase Their Migration and Invasion Sharof Tugizov, Ph.D., D.Sc., D.V.M. University of California, San Francisco 11:45 a.m. – 12 noon O6. Screening Tests for Anal High-Grade Squamous Intraepithelial Lesion Detection in U.S. Women Living With HIV Elizabeth Y. Chiao, M.D., M.P.H. Baylor College of Medicine 12 noon – 1:00 p.m. Lunch (on your own) 1:00 p.m. – 2:00 p.m. Day 1 Poster Viewing (Presenters stand by their posters.) 2:00 p.m. – 3:00 p.m. Session 3: HTLV-1 and Other Pathogens Moderators: Ashlee V. Moses, Ph.D. Oregon Health & Science University Erle S. Robertson, Ph.D. University of Pennsylvania 2:00 p.m. – 2:30 p.m. P4. HTLV-1: New Strain Genoveffa Franchini, M.D. National Cancer Institute, NIH 2:30 p.m. – 2:45 p.m. O7. Virus-like Vesicles as a Vaccine Platform for Kaposi’s Sarcoma-Associated Herpesvirus Ting-Ting Wu, Ph.D. University of California, Los Angeles 2:45 p.m. – 3:00 p.m. O8. A CRISPR Screen Reveals Epigenetic Factors That Restrict B-Cell Epstein-Barr Virus Oncoprotein Expression Benjamin E. Gewurz, M.D., Ph.D. Harvard Medical School 3:00 p.m. – 3:30 p.m. Break and Poster Viewing - 2 - 3:30 p.m. – 5:30 p.m. Session 4: Prevention of HPV-Associated Cancers and Pathobiology of Lymphoma Moderators: Elizabeth Y. Chiao, M.D., M.P.H. Baylor College of Medicine Teresa M. Darragh, M.D. University of California, San Francisco 3:30 p.m. – 4:00 p.m. P5. ANCHOR Trial Update Joel M. Palefsky, M.D., FRCP(C) University of California, San Francisco 4:00 p.m. – 4:30 p.m. P6. Recent Trends in Anal Cancer Incidence: Implications for Prevention Using Disease Simulation Modeling Ashish Deshmukh, Ph.D., M.P.H. University of Texas Health Science Center at Houston 4:30 p.m. – 5:00 p.m. P7. Evaluation of Cervical Images for Cancer Screening Using Artificial Intelligence Algorithms Mark Schiffman, M.D., M.P.H. National Cancer Institute, NIH 5:00 p.m. – 5:15 p.m. O9. PD-L1+ B-Regulatory Cells Are Induced by Exposure to Factors That Are Elevated in HIV-1+ Subjects Who Develop AIDS-NHL Laura E. Martinez, Ph.D. University of California, Los Angeles 5:15 p.m. – 5:30 p.m. O10. Potential Alternative Survival Mechanisms in HIV-Associated Diffuse Large B-Cell Lymphoma (DLBCL) of Germinal Center (GCB) Origin Alanna Maguire, Ph.D., M.Sc. Mayo Clinic Arizona 5:30 p.m. End of Day 1 - 3 - Day 2: October 22 8:00 a.m. – 8:30 a.m. Poster Day 2 Setup and Viewing Highlighted Posters (1-8) will stay up for the entire meeting. 8:30 a.m. – 8:45 a.m. Opening Comments Robert Yarchoan, M.D. Office of HIV and AIDS Malignancy National Cancer Institute, NIH Geraldina Dominguez, Ph.D Office of HIV and AIDS Malignancy National Cancer Institute, NIH 8:45 a.m. – 9:45 a.m. Session 5: Cancer Treatment and Outcomes Moderators: Richard F. Little, M.D. National Cancer Institute, NIH Richard F. Ambinder, M.D., Ph.D. Johns Hopkins University School of Medicine 8:45 a.m. – 9:15 a.m. P8. Cancer Outcomes in Patients With an Underlying HIV Infection: Anna E. Coghill, Ph.D., M.P.H. Moffitt Cancer Center 9:15 a.m. – 9:45 a.m. P9. Cancer in People Living with HIV: Treatment Disparities and Opportunities Gita Suneja, M.D., M.S.H.P. University of Utah 9:45 a.m. – 10:45 a.m. Roundtable: Cancer Treatment in the Era of cART Moderator: Richard F. Little, National Cancer Institute Discussants: Richard F. Ambinder, Surbhi Grover, Lynda Dee, Thomas S. Uldrick, Elizabeth Y. Chiao, Jeff Taylor, and Eric A. Engels 10:45 a.m. – 11:15 a.m. Break and Poster Viewing 11:15 a.m. – 12:15 p.m. Session 6: Epidemiology Moderators: Eric A. Engels, M.D., M.P.H. National Cancer Institute, NIH Keith M. Sigel, M.D. Icahn School of Medicine at Mount Sinai 11:15 a.m. – 11:30 a.m. O11. Factors Associated With Treatment Completion and Treatment Response of Chemoradiation in HIV-Infected Patients in Botswana Surbhi Grover, M.D., M.P.H. University of Pennsylvania 11:30 a.m. – 11:45 a.m. O12. Cancer-Attributable Mortality Among People With HIV in the United States During 2001-2015 Marie-Josèphe Horner, Ph.D. National Cancer Institute, NIH - 4 - 11:45 a.m. – 12 noon O13. Kaposi’s Sarcoma Incidence, Burden, and Prevalence Among Persons With HIV in the United States, 2000-2015 Sally Peprah, Ph.D. National Cancer Institute, NIH 12 noon – 12:15 p.m. O14. Cancer Immunotherapy Use and Effectiveness in Real-World Patients Living With HIV Blythe J.S. Adamson, Ph.D, M.P.H. Flatiron Health 12:15 p.m. – 1:15 p.m. Lunch (on your own) 1:15 p.m. – 2:15 p.m. Day 2 Poster Viewing (Presenters stand by their posters.) 2:15 p.m. – 3:00 p.m. Session 7: Primary Effusion Lymphoma (PEL) Moderators: Denise Whitby, Ph.D. Frederick National Laboratory for Cancer Research, NIH Thomas S. Uldrick, M.D., M.S. National Cancer Institute, NIH 2:15 p.m. – 2:45 p.m. P10. Primary Effusion Lymphoma: What Have We Learned From a Rare Disease Ethel Cesarman, M.D., Ph.D. Weill Cornell Medical College 2:45 p.m. – 3:15 p.m. P11. Gene Essentially Landscape and Druggable Genetic Vulnerabilities of Primary Effusion Lymphoma Eva Gottwein, Ph.D. Northwestern University 3:15 p.m. – 3:45 p.m. Break and Poster Viewing 3:45 p.m. – 5:30 p.m. Session 8: International Studies Moderators: Charles Wood, Ph.D. University of Nebraska-Lincoln Erle S. Robertson, Ph.D. University of Pennsylvania Medical School 3:45 p.m. – 4:15 p.m. P12. Discerning Clinical and Biological Heterogeneity in Pediatric Kaposi Sarcoma Nader K. El-Mallawany, M.D. Texas Children’s Hospital/Baylor College of Medicine 4:15 p.m. – 4:30 p.m. O15. Suspected KSHV Inflammatory Cytokine Syndrome (KICS) in Participants With Mild or Moderate AIDS-KS Enrolled in A5264/AMC067 Is Associated With Inferior Survival Scott V. Adams, Ph.D., M.P.H. Fred Hutchinson Cancer Research Center 4:30 p.m. – 4:45 p.m. O16. Treatment of Advanced AIDS-Associated Kaposi’s Sarcoma (AIDS-KS) in Resource-Limited Settings: A Three-Arm, Randomized, Non-Inferiority Trial in Sub- Saharan Africa and Brazil (ACTG A5263/AMC066) Susan E. Krown, M.D. AIDS Malignancy Consortium - 5 - 4:45 p.m. – 5:00 p.m. O17. Poor Immune Cell Infiltration in the Endemic and Epidemic Kaposi’s Sarcoma Microenvironment Salum J. Lidenge, Ph.D. University of Nebraska–Lincoln 5:00 p.m.
Load more

Recommended publications
  • Causes of Death of Cancer Patients in a Referral Hospital in Northern Iran Between 2013 and 2016
    WCRJ 2017; 4 (3): e909 CAUSES OF DEATH OF CANCER PATIENTS IN A REFERRAL HOSPITAL IN NORTHERN IRAN BETWEEN 2013 AND 2016 F. BOZORGI, A. HEDAYATIZADEH-OMRAN, R. ALIZADEH-NAVAEI, G. JANBABAEI, S. MORADI, N. SAMADAEI Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran Abstract – Objective: Cancer is a major cause of death worldwide. The first step in planning to in- crease the survival rate of cancer patients is to know the cause of death of these patients. This study aimed to investigate the causes of death in cancer patients hospitalized in Imam Khomeini hospital of Sari, Iran (a referral hospital in northern Iran). Patients and Methods: This cross-sectional study was conducted by collecting data on the caus- es of death in cancer patients who were hospitalized and passed away in Imam Khomeini hospital between 2013 and 2016 with a clinical diagnosis of cancer by an oncologist and confirmation of a pathologist. Data were collected using a questionnaire and were then analyzed by SPSS 21. Results: The most prevalent cancers were gastric, lung, breast and colon cancers and the most frequent causes of death among patients were sepsis (45.3%), carcinomatosis (16.4%), IHD (10.8%), internal bleeding (9.6%), other infections (6%) and pneumonia (3.8%). Conclusions: Infection is the most important cause of cancer deaths, while the importance of sepsis cannot be neglected. Bleeding, carcinomatosis and cardiovascular problems are also of par- ticular importance in the deaths of cancer patients. Most of cancers were related to the digestive tract, blood, and respiratory tract. A majority of these patients died from curable causes, including infection and bleeding, meaning that a large proportion of the deaths can be avoided by taking technical clinical precautions.
    [Show full text]
  • The Role of Hepatitis C Virus in Hepatocellular Carcinoma U
    Viruses in cancer cell plasticity: the role of hepatitis C virus in hepatocellular carcinoma U. Hibner, D. Gregoire To cite this version: U. Hibner, D. Gregoire. Viruses in cancer cell plasticity: the role of hepatitis C virus in hepato- cellular carcinoma. Contemporary Oncology, Termedia Publishing House, 2015, 19 (1A), pp.A62–7. 10.5114/wo.2014.47132. hal-02187396 HAL Id: hal-02187396 https://hal.archives-ouvertes.fr/hal-02187396 Submitted on 2 Jun 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution - NonCommercial - ShareAlike| 4.0 International License Review Viruses are considered as causative agents of a significant proportion of human cancers. While the very Viruses in cancer cell plasticity: stringent criteria used for their clas- sification probably lead to an under- estimation, only six human viruses the role of hepatitis C virus are currently classified as oncogenic. In this review we give a brief histor- in hepatocellular carcinoma ical account of the discovery of on- cogenic viruses and then analyse the mechanisms underlying the infectious causes of cancer. We discuss viral strategies that evolved to ensure vi- Urszula Hibner1,2,3, Damien Grégoire1,2,3 rus propagation and spread can alter cellular homeostasis in a way that increases the probability of oncogen- 1Institut de Génétique Moléculaire de Montpellier, CNRS, UMR 5535, Montpellier, France ic transformation and acquisition of 2Université Montpellier 2, Montpellier, France stem cell phenotype.
    [Show full text]
  • The Role of Viruses in the Cancerogenesis
    © 2014 by the author(s). This is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC) licencse. Published by Poznan University of Medical Sciences REVIEW PAPER DOI: https://doi.org/10.20883/medical.e60 The role of viruses in the cancerogenesis Michał Chojnicki1, Mariola Pawlaczyk2, Celina Helak-Łapaj3, Jakub Żurawski1, Krzysztof Wiktorowicz1 1 Deptartment of Biology and Environmental Protection, Poznan University of Medical Sciences, Poland 2 Deptartment of Geriatric Medicine and Gerontology, Poznan University of Medical Sciences, Poland 3 Deptartment of Bioinformatics and Computational Biology, Chair of Pathology, Poznan University of Medical Sciences, Poland ABStrACt It is estimated that seven key viruses such as Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human t-lymphotropic virus (HtLV), Human papilloma viruses (HPV), Kaposi’s sarcoma-associated herpes-virus (KSHV), Epstein-Barr virus (EBV) and Merkel cell polyomavirus (MCV), are responsible for about 11% of cancers all over the world. Viruses however are not only associated with cancerogenesis process. Scientific researches from recent years emphasize the possible use of the microorganisms as antitumor therapy. Oncoviruses, also defined as tumor viruses cause cancers whereas oncolytic viruses infect the host’s cancer cells leading to destruction of tumor and due to that they are described as cancer killing viruses. It offers the potential application of viral infections to the cancer therapy. Key words: cancers, cancerogensis, viruses. Early days na, held in 1824 in Verona, was the first documented A number of findings published within the past few suggestion of viral origins of the cancer. In his medical years have confirmed pathogens’ involvement in the practice, rigoni-Sterna learned that endometrial cancer aetiology of a significant share of human malignant was significantly more common in married women than cancers.
    [Show full text]
  • Download the Program
    The first International Congress of Neuroimmunology was held in Stresa, Italy, in 1982 and wasThe organized first International by Drs. Peter Congress O. Behan of Neuroimmunology and Federico Spreafico. was held The in secondStresa, Italy,International in Congress1982 and of wasNeuroimmunology organized by Drs. was Peter held O.in Philadelphia,Behan and Federico PA, and Spreafico. was organised The second by C.S. Raine andInternational Dale E. McFarlin. Congress It was of atNeuroimmunology this meeting in Philadelphiawas held in inPhiladelphia, 1987 that itPA, was and decided was to startorganised an international by C.S. Raine society, and the Dale International E. McFarlin. Society It was ofat Neuroimmunology,this meeting in Philadelphia and an election wasin 1987held forthat a it panel was decided of officers. to start C.S. anRaine international was elected society, President, the International John Newson-Davis Society Vice President,of Neuroimmunology, Robert Lisak andTreasurer an election and Kenethwas held Johnson for a panel Secretary, of officers. together Cedric with S. an InternationalRaine was Advisoryelected President,Board. The John Society Newson-Davis was incorporated Vice President,in 1988. Subsequent Robert Lisak meetings wereTreasurer in Jerusalem and Kenneth 1991 (Oder Johnson Abramsky Secretary, and togetherHaim Ovadia), with Amsterdaman International 1994 (KeeAdvisory Lucas), Board. Montreal 1998 (Jack Antel and Trevor Owens), Edinburgh 2001 (John Greenwood,The Society Sandra was Amor,incorporated David Baker, in 1988.John
    [Show full text]
  • CONNECTED APART Winter 2021
    CONNECTED APART Winter 2021 1 COMPOSE YOUR FUTURE qhere World-class faculty. State-of-the-art facilities you have to see (and hear) to believe. Endless performance and academic possibilities. All within an affordable public university setting ranked the number five college town in America.* Come see for yourself how the University of Iowa School of Music composes futures...one musician at a time. To apply, or for more information, visit music.uiowa.edu. *American Institute for Economic Research, 2017 MUSIC.UIOWA.EDU WINTER 2021 VIRTUAL PERFORMANCES The past year has been difficult for everyone, and we know that for many families, incomes have been reduced or become more unpredictable. To ensure that every CYSO family—no matter their CYSO is investing in the future of music and the financial situation—can enjoy our virtual performances, we've next generation of leaders. We provide music replaced our normal ticketing with a pay-what-you-can donation. education to nearly 800 young musicians ages 6-18 through full and string orchestras, jazz, CYSO virtual winter performances will debut on Saturday, steelpan, chamber music, masterclasses, music March 27, 2021 at 7:00 pm CST. For those who are able, the suggested donation is $40 (the equivalent of $10 per tick- composition and in-school programs. Students et for a family of four) to access all winter performance videos. learn from some of Chicago’s most respected Visit cyso.org/concerts to purchase your tickets. If you cannot professional musicians, perform in the world’s afford a ticket donation at this time, simply fill out the form with a great concert halls, and gain skills necessary for $0 amount to receive the performance link at no charge.
    [Show full text]
  • Commencement Program
    Sunday, the Sixteenth of May, Two Thousand and Ten ten o’clock in the morning ~ wallace wade stadium Duke University Commencement ~ 2010 One Hundred Fifty-Eighth Commencement Notes on Academic Dress Academic dress had its origin in the Middle Ages. When the European universities were taking form in the thirteenth and fourteenth centuries, scholars were also clerics, and they adopted Mace and Chain of Office robes similar to those of their monastic orders. Caps were a necessity in drafty buildings, and Again at commencement, ceremonial use is copes or capes with hoods attached were made of two important insignia given to Duke needed for warmth. As the control of universities University in memory of Benjamin N. Duke. gradually passed from the church, academic Both the mace and chain of office are the gifts costume began to take on brighter hues and to of anonymous donors and of the Mary Duke employ varied patterns in cut and color of gown Biddle Foundation. They were designed and and type of headdress. executed by Professor Kurt J. Matzdorf of New The use of academic costume in the United Paltz, New York, and were dedicated and first States has been continuous since Colonial times, used at the inaugural ceremonies of President but a clear protocol did not emerge until an Sanford in 1970. intercollegiate commission in 1893 recommended The Mace, the symbol of authority of the a uniform code. In this country, the design of a University, is made of sterling silver throughout. gown varies with the degree held. The bachelor’s Significance of Colors It is thirty-seven inches long and weighs about gown is relatively simple with long pointed Colors indicating fields of eight pounds.
    [Show full text]
  • Amy Elizabeth Herr
    Amy E. Herr, Ph.D. John D. & Catherine T. MacArthur Professor Bioengineering, University of California, Berkeley UNIVERSITY OF CALIFORNIA, Berkeley, CA 94720 BERKELEY [email protected] | herrlab.berkeley.edu EDUCATION 01/98 – 09/02 STANFORD UNIVERSITY Stanford, CA Doctor of Philosophy, Mechanical Engineering National Science Foundation Graduate Research Fellow “Isoelectric Focusing for Multi-Dimensional Separations in Microfluidic Devices” Advisors: Profs. Thomas W. Kenny & Juan G. Santiago 09/97 – 01/99 STANFORD UNIVERSITY Stanford, CA Master of Science, Mechanical Engineering National Science Foundation Graduate Research Fellow 09/93 – 06/97 CALIFORNIA INSTITUTE OF TECHNOLOGY (CALTECH) Pasadena, CA Bachelor of Science, Engineering & Applied Science with Honors APPOINTMENTS 07/19 – now JOHN D. & CATHERINE T. MACARTHUR PROFESSOR, UNIVERSITY OF CALIFORNIA, BERKELEY 07/14 – 07/19 LESTER JOHN & LYNNE DEWAR LLOYD DISTINGUISHED PROFESSOR (5-year appointment), UC BERKELEY 07/12 – 07/15 ASSOCIATE PROFESSOR, BIOENGINEERING, UNIVERSITY OF CALIFORNIA, BERKELEY 07/07 – 07/12 ASSISTANT PROFESSOR, BIOENGINEERING, UNIVERSITY OF CALIFORNIA, BERKELEY UC BERKELEY/UCSF GRADUATE GROUP IN BIOENGINEERING Directing a research group focused on design and study of microanalytical tools and methods that exploit scale-dependent physics & chemistry to address questions in the biosciences and biomedicine. Chan Zuckerberg Biohub Investigator (2017-21), National Advisory Council for Biomedical Imaging and Bioengineering (2020-23), Faculty Director of Bakar Faculty Fellows Program (2016-now), Co-Convener of Chancellor’s Advisory Committee on Life Sciences (2019-22), BioE Vice-chair for Engagement (2016- now), Director’s Council for Jacobs Institute of Design Innovation, Board Member of Chemical & Biological Microsystems Society (2013-19; Awards Chair 2016-18), Director of Bioengineering Immersion Experience (2012-22; NIH R25).
    [Show full text]
  • Testicular and Para-Testicular Tumors in South Western Nigeria
    Testicular and para-testicular tumors in south western Nigeria Salako A A1, *Onakpoya U U 1, Osasan SA2, Omoniyi-Esan G O 2 1Department of Surgery, Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria 2Department of Morbid Anatomy and Histopathology, Obafemi Awolowo University Teaching Hospitals Complex, Ile- Ife, Nigeria Abstract Background: Tumors of the testis and paratesticular tissues are rare, especially in men of African descent. In recent reviews however, the incidence is rising among the Caucasians and black Americans. We set out to determine the incidence in South- Western Nigeria and to examine the histopathologic variants. Methods: A retrospective study of patients who had histopathologically confirmed testicular and para-testicular tumours between 1989 and 2005 (17 years). Their records were documented at the Ife-Ijesha cancer registry which serves 4.7 million men residing in three states of South-Western Nigeria. Results: There were 26 cases of testicular and para-testicular tumors with an average incidence of 1.5 cases per year. The incidence of testicular cancer in our study was 0.55 per 100,000 population (95% CI, 0.52- 0.57) and accounted for 1.1% of all male cancers. Rhabdomyosarcomas were the most common variety (70% of the paratesticular tumors and 26.8% of all tumors of the testis). Seminomas comprised 50% of the germ cell tumors and 15.4% of all testicular tumors in this series. Conclusion: There still remains a low incidence of testis cancer in the South Western Nigeria. The reduction in the incidence of seminomas makes rhabdomyosarcomas the most predominant tumor in South Western Nigeria.
    [Show full text]
  • Sensitive Detection of Oncoviruses Integrated Into a Comprehensive Tumor Immuno-Genomics Platform #3788
    Sensitive detection of oncoviruses integrated into a comprehensive tumor immuno-genomics platform #3788 Gábor Bartha, Robin Li, Shujun Luo, John West, Richard Chen Personalis, Inc. | 1330 O’Brien Dr., Menlo Park, CA 94025 Contact: [email protected] Introduction Results Mixed Oncoviral Cell Lines We obtained 22 cell lines from ATCC containing HPV16, HPV18, HPV45, HPV68, HBV, EBV, KSHV, HTLV1 and HTLV2 in which the oncoviruses HPV, HBV, HCV and EBV viruses are causally EBV Cell Lines were known to be in the tumors from which the cell lines were created. In the ATCC samples we detected 23 out of 23 oncoviruses expected in linked to over 11% of cancers worldwide while both the DNA and RNA. We detected all the different types of oncoviruses that we targeted except for HCV because it wasn’t in any sample. In all KSHV, HTLV and MCV are linked to an additional To test the ability of the platform to detect oncoviruses, we identified a set of 11 EBV cell lines from but one case the signals were strong. 1%. As use of immunotherapy expands to a Coriell in which EBV was used as a transformant. We detected EBV in all the Coriell cell lines in both broader variety of cancers, it is important to DNA and RNA indicating strong sensitivity of the platform. Wide dynamic ranGe suggests quantification Detected in DNA Detected in RNA Virus Tissue Notes understand how these oncoviruses may be may be possible as well. In the DNA and RNA there were no detections of any other oncovirus EBV EBV EBV HodGkin’s lymphoma Per ATCC : “The cells are EBNA positive" indicating high specificity.
    [Show full text]
  • Nucleotide Sequences in Mouse DNA and RNA Specific for Moloney Sarcoma Virus
    Proc. Nati. Acad. Sci. USA Vol. 73, No. 10, pp. 3705-3709, October 1976 Microbiology Nucleotide sequences in mouse DNA and RNA specific for Moloney sarcoma virus (murine sarcoma virus/RNA tumor virus/nucleic acid hybridization/gene evolution/sarcoma-specific nucleotide sequence) ARTHUR E. FRANKEL AND PETER J. FISCHINGER Laboratory of Viral Carcinogenesis, National Cancer Institute, Bethesda, Maryland 20014 Communicated by Howard M. Temin, July 12,1976 ABSTRACT Complementary DNA (cDNA) synthesized (3). Laboratory strains of oncoviruses do contain information by Moloney murine sarcoma virus (M-MSV) was separated into that is different from the spontaneously released oncovirus of two parts, the first, termed MSV-specific cDNA, composed of the species Of nucleotide sequences found only in M-MSV viral RNA, and the (6, 7). these, the sarcomagenic oncoviruses gen- second, termed MSV-MuLV common cDNA, composed of nu- erally contain both a set of nucleotide sequences shared with cleotide sequences that were found in both M-MSV and murine leukosis-leukemia viruses, and another set of sequences that are leukemia virus (MuLV) viral RNAs. RNA complementary to the dissimilar from those of other oncoviruses of the species (6-10). MSV-specific cDNA was not found in several other MSV iso- Complementary DNA (cDNA) can be transcribed from sar- lates, nor in ecotropic MuLV, mouse mammary tumor virus, or coma virus RNA by the viral endogenous DNA polymerase. several murine xenotropic oncoviruses. Cellular DNA of several The cDNA represents both the "shared" and the species was examined for the presence of nucleotide sequences "specific" complementary to MSV-specific cDNA. Cells transformed by moieties of the sarcoma virus genome.
    [Show full text]
  • Oncogenic Viruses: a Potential CRISPR Treatment
    Oncogenic Viruses: A Potential CRISPR Treatment Neha Matai ∗ February 26, 2021 Abstract Oncogenic viruses promote carcinoma development by establishing long-term latent infections, obstructing tumor suppressor pathways, and transforming host cells into unchecked, proliferating malignancies. Epstein- Barr Virus, the first oncogenic virus to be discovered, can promote lym- phomagenesis in T cells, NK cells, and most commonly, resting memory B cells through the expression of oncoprotein LMP-1 and other proteins which may aid in B cell transformation. Human Papillomavirus is a com- mon infectious agent found in epithelial cells and has been shown to pro- mote malignant transformation in host cells through the overexpression of oncoproteins E6 and E7. Hepatitis C Virus, whose life cycle is not fully known yet, can also lead to carcinoma development in hepatocytes, and HCV oncoproteins NS3, NS4A, and NS5B have been associated with onco- genic roles. A novel genetic approach involving a CRISPR/Cas treatment designed to dysregulate these viral oncogenes can be used to combat these infections and their resulting carcinomas. While the long-term effects of CRISPR treatments are still being researched, this gene therapy offers a robust selection of potential treatments regarding long term diseases such as oncogenic viral infections. 1 Introduction The human population is prone to cancer through a wide variety of variables; in fact, 20% of which are caused by infectious agents such as bacteria, viruses, and other pathogens.1 Oncogenic viruses alone are responsible for 12% of all cancers diagnosed worldwide. More specifically, 80% of viral cancer cases occur in the developing world today.2 The first oncovirus was discovered in 1964 when researchers located the Epstein-Barr Virus in Burkitt’s Lymphoma cells using electron microscopy.3 Since this turning point in viral oncology, six more viruses have been confirmed to cause oncogenesis.
    [Show full text]
  • PAHO/WHO Publications on Cancer Prevention and Control CANCER SITUATION in the AMERICAS
    PAHO/WHO Publications on Cancer Prevention and Control Publications can be accessed on the PAHO website at: www.paho.org/cancer CANCER SITUATION IN THE AMERICAS Cancer in the Americas - Country Profiles Cancer in the Americas: Country profiles is a book that presents recent data, by country on cancer risk factors, cancer mortality, and cancer plans, policies and services. Cancer in the Americas – Basic Indicators Cancer in the Americas: Basic Indicators is a brochure illustrating cancer mortality data and the status of cancer prevention and control programs, by country. The brochure also includes a special analysis on cervical and breast cancer mortality trends in the Americas. Fact sheet series on cancer epidemiology This series of fact sheets presents information on the epidemiology of cancer, by type, for the leading cancers in the Americas. It provides visual data on cancer incidence and mortality for: breast, cervical, colorectal, prostate, stomach, and lung cancer. Fact sheet series on cancer in the Americas This series of factsheets presents key messages about the most common cancer types in the Americas, and how PAHO/WHO is working with Members States to address the problem. It includes information on: breast, cervical, colorectal and childhood cancers, as well as palliative care. Scan the code to download the publications CANCER CONTROL PLANNING National Cancer Control Programmes: Policies and Managerial Guidelines National Cancer Control Programmes: Policies and Managerial Guidelines provides guidance to public health professionals on how to plan comprehensive cancer control programs, using evidence based approaches. Cancer Control: Knowledge into Action Cancer control: Knowledge into Action is a series of cancer control program planning modules, that provides practical advice to program managers and policy -makers on how to advocate, plan and implement effective cancer control programs.
    [Show full text]